Month: July 2023

Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert


Excerpt from the Press Release: SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit. The funding will support the work of Albert Dahan,…

Read More

Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism


Excerpt from the Press Release: HANGZHOU, China and SAN FRANCISCO, July 11, 2023 /PRNewswire/ — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characterization, and Phase 1 clinical trial results of its GLP-1 analog ecnoglutide (XW003) in…

Read More

Velico Medical begins clinical trial on Spray Dried Plasma


Excerpt from the Press Release: BOSTON, July 12, 2023 /PRNewswire/ — Velico Medical has begun a Phase I safety study for their FrontlineODP (OnDemandPlasma) Spray Dried Plasma product in a multi-center, dose escalation clinical trial.  This first in-human clinical trial using Velico’s spray drying system is taking place at Hoxworth Blood Center, Cincinnati, Ohio; Versiti Blood Center of…

Read More

Using Medical Images in YourClinical Trial? Keep ThemWorking for You Long after Your Trial Concludes


Medical images play a pivotal role in many clinical trials today. Medical images are assets of tremendous value, yet much of that value remains untapped post trial. Why? Because Sponsors and CROs have not had the software and infrastructure necessary to aggregate and store images, or make them available. With the Fujifilm TeraMedica VNA –…

Read More

3Daughters™ Emerges as a Transformative Women’s Healthcare Company and Announces Key Leadership and Scientific Advisory Board Appointments


3Daughters aims to uniquely address and fill major gaps in Women’s Health Assembles experienced Women’s Health team and World Class SAB to advance development of novel long-acting reversible contraception technology Excerpt from the Press Release: MANSFIELD, Mass., July 13, 2023 (GLOBE NEWSWIRE) —  3Daughters, an emerging clinical development company fueling evolutionary healthcare for women, announces…

Read More

CENTOGENE Biodatabank Reveals Unique Genetic Variants in World’s Largest Niemann-Pick Type C1 Disease Cohort


Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options Excerpt from the Press Release: CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 12, 2023 (GLOBE NEWSWIRE) — CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced…

Read More

Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial


-Largest randomized trial of DynamX Bioadaptor to date with 2,400 patients enrolled, covering real-world population- Excerpt from the Press Release: MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of breakthrough cardiovascular technologies, today announced enrollment completion in INFINITY-SWEDEHEART, a prospective, multicenter, single-blind, randomized clinical trial of the DynamX® Coronary Bioadaptor System, the first metallic coronary artery implant…

Read More

Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors


Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned Excerpt from the Press Release: REHOVOT, Israel & MONMOUTH JUNCTION, N.J., July 05, 2023 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology…

Read More

ESMO GI Data: Agenus’ Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer


Median Overall Survival of 20.9 Months for Patients Without Active Liver Metastases Surpasses the Recently Reported 12.9-Month Benchmark with Standard of Care in this Population Excerpt from the Press Release: LEXINGTON, Mass.–(BUSINESS WIRE)–Immuno-oncology leader, Agenus (Nasdaq: AGEN), shared promising data today from its Phase 1b trial on the botensilimab and balstilimab combination at a late-breaking…

Read More

Status of Inclusion, Diversity, Equity and Accessibility (IDEA) in Canada’s Life Sciences Sector


The “Inclusive Life Sciences Collaboration has recently released their report on the status of IDEA in Canada’s Life Sciences Sector. “Canada aspires to accelerate growth and innovation in the life sciences sector—a goal that hinges on our ability to attract and retain talent. Embedding inclusion, diversity, equity and accessibility (IDEA) in life sciences organizations is…

Read More